As in the other tumors, PD-L1 expressing MM cells can inhibit the activity of CTLs, acquiring a proliferative advantage which results in immune evasion and resistance to anti-myeloma agents, compared with PD-L1–negative myeloma cells [34]. Here, CD274 is linked to plasma cell myeloma.